NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Eye-tracking Investigation of Clinical Measures in Multiple Sclerosis
Eye-tracking Investigation of Clinical Measures in Multiple Sclerosis
CompletedN/A
Sponsor: Innodem Neurosciences
Conditions: Multiple Sclerosis
Interventions: Eye-Tracking
Countries: Canada
The overarching goal of this research protocol is to acquire eye-tracking, cognitive, and disease-severity metrics in MS patients to train machine learning algorithms that will support the development and performance assessment of a sensitive and non-invasive eye-tracking software application. The training of our machine learning classifying algorithms to identify which eye-tracking metrics-or combination thereof-can serve as reliable markers of MS disease severity and cognitive status.
Eligibility overview
Sex: ALL
Age: 18 Years to —
Healthy volunteers: No
Study type: OBSERVATIONAL
Eligibility criteria
Inclusion Criteria: * Able to provide informed consent * Aged 18 years or older at the time of enrollment * Able to read in either French or English * Able to read the oculomotor task on-screen instructions at the testing distance (45cm) with or without corrective lenses * Confirmed diagnosis of MS as per the Macdonald criteria, irrespective of MS subtype (relapsing-remitting (RRMS), secondary-progressive (SPMS), primary-progressive (PPMS), and progressive-relapsing (PRMS)) * Neurologist-determined EDSS score between 1.0-8.0 Exclusion Criteria: * Evidence or medical history of psychiatric issues, which are known to also affect movements and oculomotor control * Presence of comorbid neurological conditions to avoid eye movement anomaly confounds (Strabismus, cranial nerve palsy, stroke-causing hemianopsia) * Diagnosis of macular edema or other pre-existing ocular conditions that would prevent a participant from performing the eye movement assessments * Having started a new prescription medication or having changed the dose of a medication known to influence ocular motor visual function (e.g. benzodiazepines, antipsychotics and anticonvulsants) within the past three months * Participants with non-disease related physical impairments to a leg, hand, or arm (e.g., broken bone or severe sprain) that would not allow completion of the assessments
Locations (1)
- Montreal, Quebec, Canada